Short Interest in Exicure, Inc. (NASDAQ:XCUR) Decreases By 47.9%

Exicure, Inc. (NASDAQ:XCUR) saw a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 16,200 shares, a decrease of 47.9% from the October 31st total of 31,100 shares. Currently, 2.0% of the company’s shares are short sold. Based on an average daily trading volume, of 1,620,000 shares, the short-interest ratio is presently 0.0 days.

Insider Activity at Exicure

In other news, major shareholder Co. Ltd. Dgp purchased 237,223 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were bought at an average cost of $3.00 per share, for a total transaction of $711,669.00. Following the acquisition, the insider now owns 849,223 shares of the company’s stock, valued at approximately $2,547,669. This trade represents a 38.76 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.90% of the stock is currently owned by insiders.

Exicure Price Performance

Shares of NASDAQ:XCUR opened at $31.99 on Friday. The firm has a market capitalization of $69.48 million, a PE ratio of -15.45 and a beta of 1.28. The business has a 50 day simple moving average of $5.76 and a two-hundred day simple moving average of $2.44. Exicure has a 1 year low of $1.44 and a 1 year high of $36.00.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.